Regeneron Pharmaceuticals, Inc.
Earlier this year, in May, Regeneron Pharmaceuticals (NASDAQ: REGN) was soaring on news of FDA approval of the Eylea injection. The market valued the company at almost $27 billion at that time. It has come down quite a bit now to nearly $25 billion. Things are now happening again at this counter, with the company preparing to submit an application for approval of Eylea for a new indication, and an more »
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection. Therefore, can these stocks go any higher? Or, have these stocks reached their peak?
New Product Launch Suggests More Upside
Regeneron Pharmaceuticals (NASDAQ: REGN) closed Tuesday down over 6% following a second quarter report that missed estimates. A particular cause for concern was the slowed sales growth for macular degeneration drug Eylea. Were investors right to run away?
If you Google Regeneron’s second quarter right now, you’ll see an odd mix of headlines touting either Eylea’s slowdown or its sales jump. So which is it? It’s more »
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector. Two eye diseases -- wet AMD (age-related macular degeneration) and DME (diabetic macular edema) -- are at the center of a big battle that includes Roche (NASDAQOTH: RHHBY), Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Ampio Pharmaceuticals (NYSEMKT: AMPE).
Wet (neovascular) AMD causes abnormal blood vessels to more »
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug. For many small and midcap biotechs, the potential of lead drugs has already led to large stock gains. Therefore, let’s look further down the pipeline at the market’s most exciting biotechs, and determine whether future upside exists.
Treating The Disease, Not The Symptoms
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company in particular, Regeneron Pharmaceuticals (NASDAQ: REGN), is crossing the line as a dual-threat developer of both kinds of drugs. Here's why that might make it worthy of your investment.
The Difference In Therapeutic Approach
Drugs that earn orphan designations treat rare diseases. Orphan drugs are more more »
On Friday we saw several stock-moving upgrades in preparation of a long week of earnings; here are four that really caught my eye. These are upgrades that I would definitely ignore.
The best of the worst
After a 64% one-year loss, Molycorp (NYSE: MCP) has gained 22% over the last month, and much of those gains have been caused by analyst upgrades. Byron Capital likes Molycorp; his “Strong Buy” rating more »
New age diversification is investing in the 21st century, and understanding that very few have the patience or the discipline to buy, hold, and forget for decades at a time.
In today’s information age, people like to be active, and follow their investments closely. Thus, new age diversification allows each investment to serve a purpose in your portfolio.
In previous Motley Fool articles, I touched on this topic with more »
There were countless market-moving upgrades on Monday morning -- but here are three in particular that I believe are most attractive and that I personally am buying.
A Bullish Day for Biotech
The entire biotech space is moving higher in response to the bid for Onyx Pharmaceuticals, especially those with Orphan blockbusters. Regeneron Pharmaceuticals (NASDAQ: REGN) is one of those stocks, but also got an upgrade to produce an extra boost more »
According to a filing with the SEC, between June 11 and June 12, Valeant Pharmaceuticals (NYSE: VRX) Board member Lloyd Segal directly purchased 2,800 shares of the stock at an average price of $83.85 per share. This gave him a total of slightly more than 21,000 shares of the stock, and came at the same time as his wife purchased close to 400 shares of Valeant.
We more »
Earnings per share, or EPS, shows the rate at which a company has grown its profitability. EPS growth is a good fundamental indicator of the future prospects of a company. Increased revenue and high profit margin drive the EPS growth of a company, and investors generally look for companies with higher EPS growth. Let’s delve into the strategies of three companies that are estimated to have more than 25 more »
Spectrum Pharmaceuticals (NASDAQ: SPPI) got crushed with a downgrade from Credit Suisse that led to a 6.3% loss on Monday. The stock is now trading at $7.50, 33% lower than it began the year (at $12). But what many don’t realize is that Spectrum at $7.50 is actually more expensive than it was at $12.00
This Is Not A Cheap Stock
Back in March, Spectrum more »
Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions and Roche's vaccine market share. This has been corrected and Motley Fool sincerely apologizes for the error.
Regeneron Pharmaceuticals (NASDAQ: REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea.
Regeneron Pharmaceuticals is a $25 more »
While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry continues to be marked by M&A. Valeant Pharmaceuticals (NYSE: VRX) is one such company that is known to swear by the philosophy of aggressive growth-by-acquisition. Last month, the company announced a mega-deal, the biggest acquisition yet by the company at $8.7 billion, to more »
Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic. It is painful experience watching kids wheezing and groaning under an attack on the playground, looking for their inhalers. A number of therapies, including tablets and inhalers, are available to treat asthma; however, asthma has no real cure to date. Current products are only meant to control asthma attacks. Therefore, patients are more »
Aegerion Pharmaceuticals (NASDAQ: AEGR) is currently trading higher by 13% after having its price target raised to $90 by Canaccord – which is now the highest target on the stock. The stock is trading at $68.50 after a one-year 380% gain due to the recent FDA approval of its drug Juxtapid. However, I believe the stock has gotten ahead of itself, and that there is no basis for a $90 more »
It’s no secret that the insiders of a company know what’s happening before us. They know trends, demand, supply, and to most of us, it makes no sense for an executive to sell shares prior to a large takeover or raised earnings guidance. Thus, when an insider sells shares we automatically assume the worst – and in some cases – we are correct!
Two Examples of Insider Selling
While investors more »
Some stocks seem to have all the luck, offering the best of both worlds. They are cutting edge or at least a bit adventuresome as their products travel into uncharted territory. Innovations that they have in their pipelines are promising to push the margins even a bit further outward some time soon. Yet, despite the fact they are moving ahead at a blazing speed, they are still managing to lay more »
Regeneron Pharmaceuticals (NASDAQ: REGN) peaked on May 14 with a price of $283.99, and has since pulled back to its current price of $260. The drugmaker has been one of the best-performing stocks of the last few years, trading higher regardless of market trend. After many years of gains, some are wondering whether now's the time to take profits. Here's why I think it's not.
A more »
It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.
It was almost a tale more »
- Page 1 of 3